CG Oncology, Inc.

Johnson & Johnson is positioning its drug and device combination, TAR-200, to overcome limitations that have often dogged the ability of various drugs to treat non-muscle-invasive bladder cancer (

A thriving market for initial public offerings is essential for biopharmaceutical industry growth as firms seek to expand drug development programs beyond the scope of what their venture capital backe

As UroGen prepares to bring a second drug to market later this year, the company is also expanding its early pipeline for long-term expansion. The company acquired a new early-stage asset, the next-ge

Pfizer is pushing ahead with its effort to jump back into immune checkpoint inhibitor therapy with new Phase III results showing efficacy for its subcutaneous PD-1 inhibitor sasanlimab in non-muscle i